Zevra Therapeutics Inc.

ZVRA | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.67

+$0.06 (+0.52%)

At close: Sep 21, 2026, 4:00 PM ET

$11.80

+$0.13 (+1.11%)

Pre-market: Sep 22, 2026, 7:23 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.52%

(1D)

Rating

Updated: Aug 24, 2026

80.5

Fundamentals Excellent

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $689.87M

1D Range

11.67 11.89

52W Range

7.51 15.04

Valuation (TTM)

PE 12.55

PB 3.17

EV/EBITDA 6.41

Valuation (NTM)

Forward PE 10.51

Forward PEG -0.78

Price Target $25.75

Cash Flow

FCF Yield 5.6%

SBC Adj. FCF Yield 3.3%

SBC Impact -41.9%

Margins

Gross Margin 95.0%

Operating Margin 28.7%

FCF Margin 28.5%

Growth (CAGR)

Revenue 3Y | 5Y 100.7% | 36.8%

Dil EPS 3Y | 5Y 532.3% | 89.1%

FCF 3Y | 5Y 222.4% | 26.8%

Returns

ROA 19.3%

ROE 32.8%

ROIC 12.9%

Financial Health

Net Cash

$221.57M

Current Ratio 5.17

Interest Coverage 6.84

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company...

Sector Healthcare

Industry Biotechnology

Employees 61

IPO Date Apr 15, 2015

Website zevra.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$24

Upside

+105.66%

Buy (7)

Hold (0)

Sell (0)

Analyst Details ➞